Schedule 13D ownership disclosure
LB Pharmaceuticals Inc
Common Stock, $0.0001 par value per share · CUSIP: 50180M108
Event date: 2025-02-06
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Deep Track Biotechnology Master Fund, Ltd.
Shares: 2,686,138.00 · Class: 9.4%
- Deep Track Special Opportunities Fund, LP
Shares: 666,666.00 · Class: 2.3%
- Deep Track Capital, LPReported CIK 0001856083
Shares: 3,352,804.00 · Class: 11.7%
- David Kroin
Shares: 3,352,804.00 · Class: 11.7%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-26-044781
- Form type
- SCHEDULE 13D/A
- Filer
- Deep Track Capital, LP
- CIK
- CIK 1856083
- Filed
- Feb 10, 2026
- Reporting period
- Feb 06, 2025
- Description
- Schedule 13D beneficial ownership